---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-24-000082"
form_type: "8-K"
ticker: null
cik: "0000910267"
company_name: "TITAN PHARMACEUTICALS INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:48:41.307122+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Titan Pharmaceuticals effects 1-for-20 reverse stock split; CUSIP changes to 888314705

## Summary
- Reverse split at 1-for-20 ratio effective January 8, 2024 at 5:00 p.m. ET.
- Stock continues trading on Nasdaq under symbol TTNP with new CUSIP 888314705.
- Approved by stockholders at special meeting on December 27, 2023 and by the Board on November 16, 2023.
- Continental Stock Transfer & Trust is exchange agent for the reverse split.

## SEC filing metadata
- accession: 0001829126-24-000082
- form_type: 8-K
- cik: 0000910267
- company_name: TITAN PHARMACEUTICALS INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/910267/000182912624000082/0001829126-24-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/910267/000182912624000082/titanpharma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-24-000082
- JSON: https://secwatch.observer/filing/0001829126-24-000082.json
- Plain text: https://secwatch.observer/filing/0001829126-24-000082.txt

## Key facts
- Governance Changes
  TITAN PHARMACEUTICALS INC: Filed Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock, effective January 8, 2024 at 5:00 p.m. Eastern Time (effective 2024-01-08).
  - Change: charter amendment
  - Effective: 2024-01-08
  source text: On January 8, 2024, Titan Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-20 (the “Reverse Split”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/910267/000182912624000082/0001829126-24-000082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.